Forty Seven

Gilead drug acquired in $5B buyout fails key blood cancer trial
Gilead drug acquired in $5B buyout fails key blood cancer trial
BioPharma Dive
Gilead Sciences
M&A
oncology
clinical trials
magrolimab
MDS
Forty Seven
Flag link:
Cancer biotech Pheast unveils $76M to expand immunotherapy’s menu to new targets
Cancer biotech Pheast unveils $76M to expand immunotherapy’s menu to new targets
MedCity News
startups
Pheast Therapeutics
Forty Seven
immunotherapy
Flag link:
Gilead taps brakes on $4.9B bet after rival's failure, pushing blood cancer data out to 2022
Gilead taps brakes on $4.9B bet after rival's failure, pushing blood cancer data out to 2022
Fierce Biotech
Gilead Sciences
Forty Seven
magrolimab
MDS
Flag link:
The top 10 largest biopharma M&A deals in 2020
The top 10 largest biopharma M&A deals in 2020
Fierce Pharma
M&A
AstraZeneca
Alexion
Bristol-Myers Squibb
MyoKardia
Gilead Sciences
Forty Seven
Merck
VelosBio
Nestle
Aimmune
Immunomedics
JNJ
Momenta Pharmaceuticals
Sanofi
Principia Biopharma
Bayer
Asklepios BioPharmaeutical
Flag link:
Astrazeneca shows megamergers were still possible in 2020
Astrazeneca shows megamergers were still possible in 2020
EP Vantage
M&A
AstraZeneca
Alexion
Bristol-Myers Squibb
MyoKardia
Bayer
Asklepios
Merck
VelosBio
Gilead Sciences
Forty Seven
Immunomedics
JNJ
Momenta
Flag link:
The top 5 pharma M&A deals of 2020
The top 5 pharma M&A deals of 2020
Pharmaforum
M&A
AstraZeneca
Alexion
Gilead Sciences
Immunomedics
Forty Seven
JNJ
Momenta
Sanofi
Principia Biopharma
Flag link:
AbbVie has 47 reasons for its $2B cancer immunotherapy partnership with I-Mab
AbbVie has 47 reasons for its $2B cancer immunotherapy partnership with I-Mab
MedCity News
AbbVie
I-Mab Biopharma
Forty Seven
lemzoparlimab
cancer immunotherapy
Flag link:
Gilead trumpets data with newly-bought magrolimab in blood cancers
Gilead trumpets data with newly-bought magrolimab in blood cancers
Pharmaforum
Gilead Sciences
ASCO 2020
Forty Seven
magrolimab
M&A
MDS
Flag link:
Biopharma acquisitions slow, but it's not Covid-19's fault yet
Biopharma acquisitions slow, but it's not Covid-19's fault yet
EP Vantage
M&A
COVID-19
Gilead Sciences
Forty Seven
Eli Lilly
Dermira
Takeda
Hypera Pharma
ANI Pharmaceuticals
Amerigen Pharma
Flag link:
A Covid-19 threat to business acquisitions
A Covid-19 threat to business acquisitions
EP Vantage
COVID-19
M&A
AbbVie
Allergan
Arya Sciences
Immatics
AcelRx
Tetraphase
Gilead Sciences
Forty Seven
Thermo Fisher
Stryker
Wright Medical
Flag link:
Forty Seven, Rocket collaborate on new treatment for Fanconi Anemia
Forty Seven, Rocket collaborate on new treatment for Fanconi Anemia
Pharmaceutical Business Review
Forty Seven
Rocket Pharmaceuticals
R&D
Fanconi Anemia
pediatric
Flag link:
Can Gilead Change Its Dim Fortunes On An Immuno-Oncology Buyout?
Can Gilead Change Its Dim Fortunes On An Immuno-Oncology Buyout?
Investors Business Daily
Gilead Scinecs
M&A
Forty Seven
immuno-oncology
Flag link:
Gilead strikes $4.9B Forty Seven acquisition, paying a hefty premium for cancer drug
Gilead strikes $4.9B Forty Seven acquisition, paying a hefty premium for cancer drug
Fierce Biotech
Gilead Sciences
M&A
Forty Seven
CD-47
Flag link:
Gilead hungry for 'don't eat me' cancer biotech: reports
Gilead hungry for 'don't eat me' cancer biotech: reports
Fierce Biotech
Gilead Sciences
Forty Seven
cancer
M&A
Flag link:
The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus
The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus
Yahoo/Benzinga
earnings
Forty Seven
Jounce Therapeutics
Catalyst Biosciences
Kodiak Sciences
Adverum Biotechnologies
IPOs
Beam Therapeutics
Flag link:
This Cancer Drug Is Driving Forty Seven's Stock Higher
This Cancer Drug Is Driving Forty Seven's Stock Higher
Motley Fool
Forty Seven
magrolimab
clinical trials
myelodysplastic syndrome
Flag link:
Forty Seven bucks the trend
Forty Seven bucks the trend
EP Vantage
Forty Seven
CD47
hematology
magrolimab
colorectal cancer
Flag link:
This Small-Cap Biotech Rose as Much as 98.3% Today
This Small-Cap Biotech Rose as Much as 98.3% Today
Motley Fool
Forty Seven
ASH2019
magrolimab
monoclonal antibodies
AML
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
Yahoo/Benzinga
ADA
Merck
Keytruda
NGM Biopharmaceuticals
NGM313/MK-3655
Corbus Pharmaceuticals
Nektar
Galapagos
Kezar Life Sciences
Kura Oncology
Bluebird Bio
BeiGene
Global Blood Therapeutics
Blueprint Medicines
Regeneron
Arqule
Sunesis
Sutro BioPharma
Incyte
Geron
Forty Seven
Flag link:
May 15 ASCO Quick Takes: After-hours pop for Iovance, MacroGenics; plus Takeda, Amgen, Forty Seven
May 15 ASCO Quick Takes: After-hours pop for Iovance, MacroGenics; plus Takeda, Amgen, Forty Seven
BioCentury
Iovance
LN-145
cervical cancer
Takeda
TAK-788
non-small cell lung cancer
Amgen
AMG-510
Macrogenics
margetuximab
HER2-positive metastatic breast cancer
Forty Seven
Flag link:

Pages